Aviles RJ, Martin DO, Apperson HC, et al. Inflammation as a risk factor for atrialfibrillation[J]. Circulation, 2003, 108(24): 3006-3010.
[2]
Healery JS, Morillo CA, Connooly SJ. Role of the reninangiotensin-aldosterone system in atrial fibrillation and cardiac remodeling[J]. Cur Opin Cardiol, 2005, 20(1): 31-37.
[3]
Watanabe E, Arakawa T, Uchiyama T, et al. High sensitivity C reaction protein is predictive of succesful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion[J]. Int J Cardiol, 2006, 108(3): 346-353.
[4]
Dernellis JM, Paneratou MP. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation[J]. Eur Heart J, 2004, 25(13): 1100-1107.
[5]
Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: result from the Valsartan heart failure trial[J]. Am Heart J, 2005, 149(3): 548.
[6]
Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation[J]. Cardiovas Res, 2002, 54(2): 230-246.
